Company Encyclopedia
View More
name
SHENGDA BIO-PHARM
603079.SH
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin and natamycin; and intermediate APIs. The company is based in Tiantai, China.
3.136 T
603079.SHMarket value -Rank by Market Cap -/-

Financial Score

11/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking71/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.32%C
    • Profit Margin7.27%B
    • Gross Margin22.78%D
  • Growth ScoreB
    • Revenue YoY6.01%C
    • Net Profit YoY312.87%A
    • Total Assets YoY23.37%A
    • Net Assets YoY25.90%A
  • Cash ScoreB
    • Cash Flow Margin1374.85%B
    • OCF YoY6.01%C
  • Operating ScoreC
    • Turnover0.43C
  • Debt ScoreB
    • Gearing Ratio25.26%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SHENGDA BIO-PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 53.34 million yuan, a year-on-year increase of 146.04%

    According to the Zhitong Finance APP, SHENGDA BIO-PHARM disclosed its third-quarter report for 2025. The company achieved revenue of 621 million yuan in the first three quarters, a year-on-year increase of 2.04%; net profit attributable to the parent company was 53.34 million yuan, a year-on-year increase of 146.04%; net profit excluding non-recurring gains and losses was 47.49 million yuan, a year-on-year increase of 393.96%; basic earnings per share were 0.30 yuan

    Zhitong·
    SH
    603079
    -3.27%
    Zhitong·
    SH
    603079
    -3.27%

    SHENGDA BIO-PHARM released its first-quarter performance, with a net profit attributable to the parent company of 21.7095 million yuan, a year-on-year increase of 469.35%

    SHENGDA BIO-PHARM released its Q1 2025 performance report, with operating revenue of 203 million yuan, a year-on-year increase of 9.95%. The net profit attributable to the parent company was 21.7095 million yuan, a year-on-year increase of 469.35%; the net profit after deducting non-recurring gains and losses was 19.7178 million yuan, a year-on-year increase of 1749.87%. The basic earnings per share were 0.13 yuan/share

    Zhitong·
    SH
    603079
    -3.27%
    Zhitong·
    SH
    603079
    -3.27%

    Synthetic biology concept stocks strengthen, SHENGDA BIO-PHARM hits the daily limit in the afternoon

    On April 10th, synthetic biology concept stocks strengthened. As of 14:23, SHENGDA BIO-PHARM hit the daily limit, Sanyuan Biotechnology, BLB, SC Pharmaceuticals, and Kingdomway had previously hit the daily limit, while Jinbo Biotechnology and Wuxi Jinghai rose over 10%

    Zhitong·
    SH
    603079
    -3.27%
    SZ
    301206
    -1.44%
    SZ
    002286
    -3.64%
    Zhitong·
    SH
    603079
    -3.27%
    SZ
    301206
    -1.44%
    SZ
    002286
    -3.64%

    SHENGDA BIO-PHARM: Wanjian Investment reduced its stake in the company by 1.36%

    SHENGDA BIO-PHARM announced that WanJian Investment reduced its shareholding in the company by 1.36%, totaling 2.3284 million shares, with the shareholding ratio decreasing from 19.08% to 17.72%. This reduction does not trigger a mandatory takeover bid, and the controlling shareholder and actual controller have not changed. The total shareholding of WanJian Investment and its concerted parties decreased from 94.1539 million shares to 91.8255 million shares, accounting for a total share capital ratio decrease from 55.00% to 53.64%

    Zhitong·
    SH
    603079
    -3.27%
    Zhitong·
    SH
    603079
    -3.27%

    SHENGDA BIO-PHARM and others established a technology company including retail business for publications

    According to the Qichacha APP, recently, Tiantai Miaoxin Technology Co., Ltd. was established, with Fang Xin as the legal representative and a registered capital of 1 million yuan. The business scope includes: internet sales of publications; retail of publications; basic telecommunications services; second-class value-added telecommunications services, etc. Qichacha's equity penetration shows that the company is jointly held by SHENGDA BIO-PHARM and others

    Zhitong·
    SH
    603079
    -3.27%
    Zhitong·
    SH
    603079
    -3.27%
    © 2025 Longbridge｜Disclaimer